Patent ID: 11946934
Assignee: WELLMARKER BIO CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G  C | IPC C  G

Claim 0:
1. A method for treating colon cancer in a human subject comprising:
(a) measuring the expression level of an active form of RON(Recepteur d′Origine Nantais) within a biological sample obtained from the human subject with an agent selected from, an antisense oligonucleotide, a primer pair, or a probe which specifically binds to mRNA of the active RON or an antibody, a peptide, or a nucleotide that specifically binds to the active RON protein,
wherein the active RON is at least one selected from the group consisting of a phosphorylated RON; α splicing variant which is RONΔ155 of SEQ ID NO: 1; α splicing variant which is RONΔ160 of SEQ ID NO: 2; α splicing variant which is RONΔ165 of SEQ ID NO: 3; a mutant in which the 1254th amino acid in the polypeptide of SEQ ID NO: 4 is substituted from M to T; a mutant in which the 1335th amino acid in the polypeptide of SEQ ID NO: 4 is substituted from R to G; a mutant in which the 523rd amino acid in the polypeptide of SEQ ID NO: 4 is substituted from R to Q; a mutant in which the 1232nd amino acid in the polypeptide of SEQ ID NO: 4 is substituted from D to V; and a mutant in which the 1268th amino acid in the polypeptide of SEQ ID NO: 4 is substituted from M to T;
(b) detecting increased expression of active RON in the biological sample as compared to a control level;
(c) determining that the human subject is sensitive to a c-MET protein kinase inhibitor; and
(d) administering the c-Met protein kinase inhibitor to the human subject who has been determined to be sensitive to the c-Met inhibitor
wherein the protein kinase inhibitor is at least one selected from the group consisting of CJ12495, CJ12537, CJ12524, and CJ12567.